ヨーロッパのIgG4関連疾患市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2021 –2028 |
 市場規模（基準年） |
USD 713.58 Million |
 Market Size (Forecast Year) |
USD 925.98 Million |
 CAGR |
% |
| 主要市場プレーヤー |
>ヨーロッパのIgG4関連疾患市場、疾患タイプ別（1型（IgG4関連）自己免疫性膵炎（AIP）、後腹膜線維症、IgG4関連尿細管間質性腎炎（TIN）、IgG4関連硬化性胆管炎、IgG4関連涙腺炎および唾液腺炎、IgG4関連硬膜炎、IgG4関連甲状腺疾患、血清IgG4濃度、その他）、タイプ別（診断および治療）、投与経路（非経口、経口、その他）、エンドユーザー（病院、専門クリニック、その他）、流通チャネル（病院薬局、小売薬局、オンライン薬局、その他）、国別（ドイツ、フランス、英国、ハンガリー、リトアニア、オーストリア、アイルランド、ノルウェー、ポーランド、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他）ヨーロッパ）。2028年までの業界動向と予測
市場分析と洞察: ヨーロッパの IgG4 関連疾患市場
欧州のIgG4関連疾患市場は、2021年から2028年の予測期間に大幅な成長が見込まれています。データブリッジマーケットリサーチは、欧州のIgG4関連疾患市場は2021年から2028年の予測期間に3.7%のCAGRで成長し、2020年の7億1,358万米ドルから2028年には9億2,598万米ドルに達すると分析しています。IgG4関連疾患グループに関する広範な研究により、すべての臓器と形態におけるその発現を分類および特定し、決定的な診断のためのより優れた医療技術にアクセスすることが、予測期間中の市場の成長を促進すると予想される主要な要因です。
IgG4関連疾患に罹患する人はますます増えており、リスクを最小限に抑えるためには、非常に効果的で高度な治療が必要です。医療制度では、患者の治療中に、さまざまな種類のIgG4関連疾患に対する高度な医薬品を必要としています。そのため、主要な市場プレーヤーは、製品の発売と承認に重点を置いています。さらに、政府と規制当局は、製品承認によって市場プレーヤーをサポートしています。
技術の進歩は、ヨーロッパのIgG4関連疾患市場の原動力となっています。一方で、治療費の高さは市場の成長を阻害する可能性があります。医療費の増加は市場の成長のチャンスとなる可能性があります。しかし、COVID-19の出現により、病気の診断が遅れ、ヨーロッパのIgG4関連疾患市場の成長に課題をもたらしています。
欧州 IgG4 関連疾患市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益への影響ソリューションを作成し、希望する目標を達成できるようお手伝いします。
欧州IgG4関連疾患市場の範囲と市場規模
ヨーロッパの IgG4 関連疾患市場は、疾患の種類、タイプ、投与経路、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 疾患タイプに基づいて、欧州のIgG4関連疾患市場は、タイプ1（IgG4関連）自己免疫性膵炎（AIP）、後腹膜線維症、IgG4関連尿細管間質性腎炎（TIN）、IgG4関連硬化性胆管炎、IgG4関連涙腺炎および唾液腺炎、IgG4関連硬膜炎、IgG4関連甲状腺疾患、血清IgG4濃度、その他に分類されます。 2021年には、人口の間でこの疾患タイプの有病率が高まっているため、IgG4関連涙腺炎および唾液腺炎セグメントが市場を支配すると予想されます。
- タイプ別に見ると、ヨーロッパのIgG4関連疾患市場は診断と治療に分かれています。2021年には、この疾患に対する認識の高まりにより、診断セグメントが主流になると予想されます。
- 投与経路に基づいて、欧州のIgG4関連疾患市場は、経口、非経口、その他に分類されます。2021年には、非経口セグメントが最も効果的な投与方法であるため、市場を支配すると予想されます。
- エンドユーザーに基づいて、ヨーロッパのIgG4関連疾患市場は、病院、専門クリニック、その他に分類されます。2021年には、自己免疫疾患患者のプールが大きいため、病院のセグメントが市場を支配すると予想されます。
- 流通チャネルに基づいて、ヨーロッパのIgG4関連疾患市場は、病院薬局、小売薬局、オンライン薬局、その他に分類されます。2021年には、医療費の増加により、病院薬局セグメントが市場を支配すると予想されます。
欧州IgG4関連疾患市場の国別分析
ヨーロッパの IgG4 関連疾患市場が分析され、疾患の種類、タイプ、投与経路、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。
ヨーロッパの IgG4 関連疾患市場レポートで取り上げられている国は、ドイツ、フランス、英国、ハンガリー、リトアニア、オーストリア、アイルランド、ノルウェー、ポーランド、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他のヨーロッパ諸国です。
IgG4関連疾患グループに関する広範な研究により、この地域のすべての臓器と形態におけるその発現を分類および特定しているため、ヨーロッパはIgG4関連疾患市場を支配すると予想されています。IgG4関連疾患に対する認識が高まっているため、ドイツが市場を支配し、ヨーロッパのIgG4関連疾患市場をリードしています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、ヨーロッパ ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
欧州のIgG4関連疾患市場における医療費の増加とイノベーションおよび技術の進歩により、プレーヤーに新たな機会が生まれています。
IgG4関連疾患は、ヨーロッパの疾患タイプ別セグメントが最も高い成長率で成長すると予想されています。ドイツはヨーロッパの市場をリードしており、IgG4関連疾患の治療薬の需要が高まっているため、IgG4関連疾患のIgG4関連涙腺炎および唾液腺炎セグメントが同国で主流となっています。
ヨーロッパの IgG4 関連疾患市場では、ヨーロッパの IgG4 関連疾患市場の売上、ヨーロッパの IgG4 関連疾患市場の発展の影響、ヨーロッパの IgG4 関連疾患市場への支援に関する規制シナリオの変化など、特定の業界における各国の成長に関する詳細な市場分析も提供されます。データは 2010 年から 2019 年までの履歴期間で利用できます。
競争環境と欧州IgG4関連疾患市場シェア分析
ヨーロッパの IgG4 関連疾患市場の競争環境は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、および技術ライフライン曲線が含まれます。上記のデータ ポイントは、ヨーロッパの IgG4 関連疾患市場への企業の重点にのみ関連しています。
欧州IgG4関連疾患レポートで取り上げられている主要企業は、Zydus Cadila、Hikma Pharmaceuticals PLC、Sun Pharmaceutical Industries Ltd.、Baxter、Viatris Inc.、Amgen Inc.、Sandoz International GmbH（Novartis AGの子会社）、Fresenius Kabi USA（Fresenius SE & Co. KGaAの子会社）、Pfizer Inc.、Cipla Inc.、Celltrion Healthcare Co., Ltd.、Amneal Pharmaceuticals LLC.、Accord-UK Ltd.、Ingenus Pharmaceuticals、SEBELA PHARMACEUTICAL、およびその他の国内および欧州の企業です。DBMRアナリストは、競争上の強みを理解し、各競合他社の競合分析を個別に提供します。
世界中の企業によって多くの製品の発売や契約も開始されており、ヨーロッパのIgG4関連疾患市場がさらに加速しています。
例えば、
- 2019年12月、アムニール・ファーマシューティカルズ社は、米国サンフランシスコで開催された第38回JPモルガンヘルスケアカンファレンスでプレゼンテーションを行いました。同社が行ったこのプレゼンテーションにより、製品の需要と売上が増加し、将来の収益増加につながりました。
- 2020年11月、アコードヘルスケア社は、グローバルジェネリック＆バイオシミラーアワード2020で最も評価された企業であり、年間最優秀企業賞、年間最優秀規制功績賞、年間最優秀企業責任イニシアチブ賞を受賞したことを発表しました。これにより、製品の売上と需要が増加し、収益創出に貢献しています。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE IGG4-RELATED DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 SUMMARY WRITE UP (NORTH AMERICA)
5.1.1 OVERVIEW
5.2 SUMMARY WRITE UP (EUROPE)
5.2.1 OVERVIEW
5.3 SUMMARY WRITE UP (ASIA-PACIFIC)
5.3.1 OVERVIEW
5.4 SUMMARY WRITE UP (SOUTH AMERICA)
5.4.1 OVERVIEW
5.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)
5.5.1 OVERVIEW
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR EUROPE IGG4-RELATED DISEASE MARKET
7.1 U.S. REGULATORY FRAMEWORK
7.2 EUROPE REGULATORY FRAMEWORK
7.3 JAPAN REGULATORY FRAMEWORK
8 PIPELINE ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING AWARENESS ABOUT IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)
9.1.2 ESCALATION IN INNOVATION AND TECHNOLOGIES
9.1.3 INCREASE IN RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
9.2 RESTRAINTS
9.2.1 HIGH COST OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) TREATMENT
9.2.2 ADVERSE EFFECTS ASSOCIATED WITH TREATMENT
9.3 OPPORTUNITIES
9.3.1 RISING EXPENDITURE ON HEALTHCARE
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
9.4 CHALLENGE
9.4.1 DIFFICULT DIAGNOSIS AND MANGEMENT OF THE DISEASE
10 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS
11.3 RETROPERITONEAL FIBROSIS
11.4 IGG4-RELATED THYROID DISEASE
11.5 IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN)
11.6 IGG4-RELATED SCLEROSING CHOLANGITIS
11.7 TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP)
11.8 IGG4-RELATED PACHYMENINGITIS
11.9 OTHERS
12 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSTIC
12.2.1 IMAGING
12.2.1.1 COMPUTED TOMOGRAPHY (CT)
12.2.1.2 MAGNETIC RESONANCE IMAGING (MRI)
12.2.1.3 PET/CT
12.2.1.4 OTHERS
12.2.2 LABORATORY TESTING (SERUM IGG4 CONCENTRATION)
12.2.3 FLOW CYTOMETRY
12.2.4 OTHERS
12.3 TREATMENT
12.3.1 RITUXIMAB
12.3.2 CYCLOPHOSPHAMIDE
12.3.3 METHOTREXATE
12.3.4 STEROIDS
12.3.4.1 Methylprednisolone
12.3.4.2 Prednisolone
12.3.4.3 others
12.3.5 AZATHIOPRINE
12.3.6 OTHERS
13 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.3 ORAL
13.4 OTHERS
14 EUROPE IGG4-RELATED DISEASE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 EUROPE IGG4-RELATED DISEASE MARKET, BY REGION
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 U.K.
16.1.4 SWITZERLAND
16.1.5 NETHERLANDS
16.1.6 ITALY
16.1.7 SPAIN
16.1.8 AUSTRIA
16.1.9 RUSSIA
16.1.10 HUNGARY
16.1.11 IRELAND
16.1.12 NORWAY
16.1.13 POLAND
16.1.14 TURKEY
16.1.15 BELGIUM
16.1.16 LITHUANIA
16.1.17 REST OF EUROPE
17 EUROPE IGG4-RELATED DISEASE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 AMGEN INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GENENTECH, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 CELLTRION HEALTHCARE CO., LTD.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACCORD-UK LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AMNEAL PHARMACEUTICALS LLC
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ANI PHARMACEUTICALS, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 ANTARES PHARMA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BAXTER
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CIPLA INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 HIKMA PHARMACEUTICALS PLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 INGENUS PHARMACEUTICALS
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 LANNETT
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 SEBELA PHARMACEUTICALS
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 STI PHARMA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 VIATRIS INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 ZYDUS CADILA
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 COMPANIES WITH PRODUCTS IN PHASE II AND PHASE III CLINICAL TRIALS
20.1 SANOFI
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.2 XENCOR
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 BRISTOL-MYERS SQUIBB COMPANY
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 HORIZON THERAPEUTICS PLC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表のリスト
TABLE 1 EUROPE IGG4-RELATED DISEASE MARKET, PIPELINE ANALYSIS
TABLE 2 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 3 EUROPE IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 4 EUROPE RETROPERITONEAL FIBROSIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 EUROPE IGG4-RELATED THYROID DISEASE IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 6 EUROPE IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 7 EUROPE IGG4-RELATED SCLEROSING CHOLANGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 EUROPE TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 EUROPE IGG4-RELATED PACHYMENINGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 12 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 13 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 14 EUROPE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 15 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 17 EUROPE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 18 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 19 EUROPE PARENTERAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 20 EUROPE ORAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 EUROPE IGG4-RELATED DISEASE MARKET, BY END USERS, 2019-2028 (USD THOUSAND)
TABLE 23 EUROPE HOSPITALS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 24 EUROPE SPECIALTY CLINICS IN EUROPE IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 25 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 26 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 27 EUROPE HOSPITAL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 28 EUROPE RETAIL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 29 EUROPE ONLINE PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 30 EUROPE OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 31 EUROPE IGG4-RELATED DISEASE MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 32 EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 EUROPE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 34 EUROPE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 35 EUROPE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 36 EUROPE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 EUROPE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 EUROPE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 39 EUROPE IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 40 EUROPE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 41 GERMANY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 42 GERMANY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 43 GERMANY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 44 GERMANY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 45 GERMANY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 46 GERMANY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 47 GERMANY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 48 GERMANY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 49 GERMANY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 50 FRANCE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 51 FRANCE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 52 FRANCE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 53 FRANCE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 54 FRANCE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 55 FRANCE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 56 FRANCE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 57 FRANCE IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 58 FRANCE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 59 U.K. IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 60 U.K. IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 61 U.K. DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 62 U.K. IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 63 U.K. TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 64 U.K. STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 65 U.K. IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 66 U.K. IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 67 U.K. IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 68 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 69 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 70 SWITZERLAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 71 SWITZERLAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 72 SWITZERLAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 73 SWITZERLAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 74 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 75 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 76 SWITZERLAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 77 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 78 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 79 NETHERLANDS DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 80 NETHERLANDS IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 81 NETHERLANDS TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 82 NETHERLANDS STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 83 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 84 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 85 NETHERLANDS IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 86 ITALY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 87 ITALY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 88 ITALY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 89 ITALY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 90 ITALY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 91 ITALY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 92 ITALY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 93 ITALY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 94 ITALY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 95 SPAIN IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 96 SPAIN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 97 SPAIN DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 98 SPAIN IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 99 SPAIN TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 100 SPAIN STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 101 SPAIN IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 102 SPAIN IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 103 SPAIN IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 104 AUSTRIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 105 AUSTRIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 106 AUSTRIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 107 AUSTRIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 108 AUSTRIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 109 AUSTRIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 110 AUSTRIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 111 AUSTRIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 112 AUSTRIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 113 RUSSIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 114 RUSSIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 115 RUSSIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 116 RUSSIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 117 RUSSIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 118 RUSSIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 119 RUSSIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 120 RUSSIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 121 RUSSIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 122 HUNGARY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 123 HUNGARY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 124 HUNGARY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 125 HUNGARY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 126 HUNGARY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 127 HUNGARY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 128 HUNGARY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 129 HUNGARY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 130 HUNGARY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 131 IRELAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 132 IRELAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 133 IRELAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 134 IRELAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 135 IRELAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 136 IRELAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 137 IRELAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 138 IRELAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 139 IRELAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 140 NORWAY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 141 NORWAY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 142 NORWAY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 143 NORWAY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 144 NORWAY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 145 NORWAY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 146 NORWAY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 147 NORWAY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 148 NORWAY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 149 POLAND IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 150 POLAND IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 151 POLAND DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 152 POLAND IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 153 POLAND TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 154 POLAND STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 155 POLAND IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 156 POLAND IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 157 POLAND IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 158 TURKEY IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 159 TURKEY IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 160 TURKEY DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 161 TURKEY IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 162 TURKEY TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 163 TURKEY STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 164 TURKEY IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 165 TURKEY IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 166 TURKEY IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 167 BELGIUM IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 168 BELGIUM IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 169 BELGIUM DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 170 BELGIUM IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 171 BELGIUM TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 172 BELGIUM STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 173 BELGIUM IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 174 BELGIUM IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 175 BELGIUM IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 176 LITHUANIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 177 LITHUANIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 178 LITHUANIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 179 LITHUANIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 180 LITHUANIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 181 LITHUANIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 182 LITHUANIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 183 LITHUANIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 184 LITHUANIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 185 REST OF EUROPE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
図表一覧
FIGURE 1 EUROPE IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 2 EUROPE IGG4-RELATED DISEASE MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE IGG4-RELATED DISEASE MARKET : DROC ANALYSIS
FIGURE 4 EUROPE IGG4-RELATED DISEASE MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE IGG4-RELATED DISEASE MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE IGG4-RELATED DISEASE MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE IGG4-RELATED DISEASE MARKET : DBMR MARKET POSITION GRID
FIGURE 8 EUROPE IGG4-RELATED DISEASE MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE IGG4-RELATED DISEASE MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 11 INCREASING AWARENESS FOR IGG4-RELATED DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE IGG4-RELATED DISEASE MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE IGG4-RELATED DISEASE MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: EUROPE IGG4-RELATED DISEASE MARKET
FIGURE 14 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2020
FIGURE 15 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
FIGURE 16 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 17 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 18 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, 2020
FIGURE 19 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, 2019-2028 (USD THOUSAND)
FIGURE 20 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 21 EUROPE IGG4-RELATED DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 23 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
FIGURE 24 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 25 EUROPE IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, 2020
FIGURE 27 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, 2019-2028 (USD THOUSAND)
FIGURE 28 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 29 EUROPE IGG4-RELATED DISEASE MARKET: BY END USERS, LIFELINE CURVE
FIGURE 30 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 31 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
FIGURE 32 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL,CAGR (2021-2028)
FIGURE 33 EUROPE IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE IGG4-RELATED DISEASE MARKET: SNAPSHOT (2020)
FIGURE 35 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020)
FIGURE 36 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2021 & 2028)
FIGURE 37 EUROPE IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020 & 2028)
FIGURE 38 EUROPE IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 39 EUROPE IGG4-RELATED DISEASEMARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
